A Quick Transition From Research Firm To Clinical-Phase Biotech

By Ed Miseta, Chief Editor, Clinical Leader

To say the last two years have been a whirlwind for Anne Whitaker would likely be an understatement.

In October 2018, with more than two decades of senior-level leadership experience in the pharma industry, Anne Whitaker joined small biotech Dance Biopharma as its CEO. Nearly a year later she helped spearhead a name change to Aerami Therapeutics and a move of its headquarters to Durham, NC. Oh, and throughout all of that she had to figure out how to transition the company from a research firm to a clinical-phase company. It’s been a complicated and challenging journey.